WSA
FPRX

Wall Street Associates’s Five Prime Therapeutics, Inc. FPRX Stock Holding History

Wall Street Associates’s Portfolio FPRX Stock Details FPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2014
Q1 		– Sell
-25,000
Closed -$420K – 349
2013
Q4 		$420K Hold
25,000
– – 0.03% 280
2013
Q3 		$327K Buy
+25,000
New +$338K 0.03% 287

Other funds holding FPRX

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TGHSA
TPG Group Holdings (SBS) Advisors Fort Worth, Texas $10.1B AUM 22.58% 1-Year Est. Return
EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
HM
HealthCor Management New York $109M AUM 10.64% 1-Year Est. Return
WT
Wellcome Trust London, United Kingdom $9.01B AUM 12.05% 1-Year Est. Return

Wall Street Associates's FPRX Position: Q1 2014 in Review

Wall Street Associates sold out of Five Prime Therapeutics, Inc. (FPRX) in Q1 2014, closing a stake of 25,000 shares — an estimated $420K sold.

Wall Street Associates first reported a position in FPRX in Q3 2013 and held it in 2 quarters. The position peaked at $420K in Q4 2013. 56 funds tracked by Wall St. Rank hold FPRX as of Q1 2014.

  • Wall Street Associates reported no remaining Five Prime Therapeutics, Inc. position as of Q1 2014 after selling out during the quarter.
  • Wall Street Associates sold 25,000 Five Prime Therapeutics, Inc. shares in Q1 2014, an estimated $420K.
  • Wall Street Associates first reported a position in Five Prime Therapeutics, Inc. in Q3 2013 and held it in 2 quarters.
  • Wall Street Associates's Five Prime Therapeutics, Inc. position peaked at $420K in Q4 2013.
  • 56 funds tracked by Wall St. Rank held Five Prime Therapeutics, Inc. as of Q1 2014.

Based on Wall Street Associates's 13F filing for Q1 2014, filed 13 May 2014.